// App-Quantinova.ai

8054 : Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after 2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial.

Researchers

Presenter

  • Paul G. Richardson

Principal Investigators

  • Sagar Lonial

  • Robert L. Schlossman

  • Anuja Nidumolu Roy

  • Istvan Majer

  • Ashok Panneerselvam

  • Monika Sopala

  • Jesus San Miguel

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

  • Novartis, East Hanover, NJ

  • Pharmerit International, Rotterdam, Netherlands

  • Novartis Oncology, Randolph, NJ

  • Novartis AG, Basel, Switzerland

  • Clinica Universidad de Navarra, Pamplona, Spain

Locations

  • United States

  • Spain

  • Switzerland

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Panobinostat

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Controlled

Phase

  • III

Study Id's

  • NCT01023308

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved